GLUE Monte Rosa Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Monte Rosa Therapeutics, Inc. (GLUE) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 17, 2026, a 10-Q quarterly report filed on May 7, 2026, an 8-K current report filed on August 6, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Monte Rosa Therapeutics, Inc. (GLUE) (SEC CIK 1826457), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Monte Rosa Therapeutics, Inc.
Ask AI about GLUE filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting GLUE positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on GLUE.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Monte Rosa Therapeutics, Inc. (GLUE) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 6, 2026 | - | - | - |
8-K | Jun 11, 2026 | - | - | - |
10-Q | May 7, 2026 | Mar 31, 2026 | - | |
8-K | May 7, 2026 | - | - | |
8-K | Mar 17, 2026 | - | Analysis | - |
10-K | Mar 17, 2026 | Dec 31, 2025 | - | |
8-K | Feb 10, 2026 | - | - | |
8-K | Jan 9, 2026 | - | - | |
8-K | Jan 7, 2026 | - | - | |
8-K | Jan 7, 2026 | - | - | |
8-K | Dec 16, 2025 | - | - | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
10-Q | May 8, 2025 | Mar 31, 2025 | - | |
10-K | Mar 20, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | - | |
10-Q | May 9, 2024 | Mar 31, 2024 | - | |
10-K | Mar 14, 2024 | Dec 31, 2023 | - | |
SC 13G | Feb 14, 2024 | - | - | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | - | |
10-Q | May 11, 2023 | Mar 31, 2023 | - | |
10-K | Mar 16, 2023 | Dec 31, 2022 | - | |
SC 13G | Feb 3, 2023 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate GLUE share value held by 13F filers tracked by SignalX, by quarter.
- BlackRock+1.46M (+35%)
- State Street Corp+1.25M (+59%)
- Goldman Sachs Group+705.6K (+238%)
- Dimensional Fund Advisors+473.0K (+83%)
- Citadel Advisors LLC+233.7K (+277%)
- FMR LLC (Fidelity)275.8K (-21%)
- AQR Capital Management126.6K (-16%)
- Morgan Stanley121.5K (-15%)
- Ameriprise Financial86.2K (-71%)
- Alphabet Inc60.7K (-8%)
- Renaissance Technologies LLC+379.1K
- Franklin Resources+199.7K
- Prudential Financial+56.3K
- Principal Financial Group+42.4K
- Allstate+28.0K
- Vanguard Group Inc−3.25M
- Invesco Ltd−362.2K
- JPMorgan Chase & Co−24.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest GLUE SEC filings in 2026?
Monte Rosa Therapeutics, Inc. (GLUE) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did GLUE file its most recent 10-K annual report?
Monte Rosa Therapeutics, Inc. (GLUE) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view GLUE 10-Q quarterly reports?
Monte Rosa Therapeutics, Inc. (GLUE)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every GLUE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has GLUE filed recently?
Monte Rosa Therapeutics, Inc. (GLUE)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find GLUE insider trading activity (Form 4)?
SignalX aggregates every GLUE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does GLUE file with the SEC?
Monte Rosa Therapeutics, Inc. (GLUE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GLUE filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Monte Rosa Therapeutics, Inc. (GLUE).
What is GLUE's SEC CIK number?
Monte Rosa Therapeutics, Inc. (GLUE)'s SEC CIK (Central Index Key) number is 1826457. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1826457 to look up all GLUE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Monte Rosa Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 38+ filings.